Humanigen, Inc. (HGEN) News
Filter HGEN News Items
HGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest HGEN News From Around the Web
Below are the latest news stories about HUMANIGEN INC that investors may wish to consider to help them evaluate HGEN as an investment opportunity.
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association CongressOf the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously reported positive clinical responses, these additional data demonstrate statistically significant and clinically relevant improvements in hematologic outcomes, along with improvements in inflammatory markers, that occur in the early months after treatment initiation and appear durableCMML |
Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of LeukemiaCMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix evaluable subjects, including those with high risk CMML, demonstrated clinical benefit at three months follow-upLenzilumab appears to be well-toleratedShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty L |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off another day of trading with a breakdown of the biggest pre-market stock movers for trader need to kno about Wednesday! |
Humanigen Reports Third Quarter 2022 Financial ResultsShort Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strateg |
Humanigen Announces Participation and Presentation at Jefferies London Healthcare ConferenceShort Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinica |
Humanigen Announces Retention of SC&H Capital as Financial AdvisorShort Hills, New Jersey--(Newsfile Corp. - October 31, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced it has engaged SC&H Capital, an affiliate of SC&H Group, to advise Humanigen on exploration of strategic options. SC&H is an investment banking and advisory firm providing merger and acquisition (M&A), financial restructuring and related business a |
Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMMLAdditional Clinical Sites Expected to Enroll CMML Patients in Australia Short Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - September 12, 2022) - Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty Ltd, ("Humanigen") and the South Australian Health and Medical Research Institute ("SAHMRI") today announced an expansion of the ongoing development Precision Approach to Chronic Myelomonocytic Leukemia ("PREACH-M") study of lenzilumab in chronic myelomonocytic leukemia ("CMML |
Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022Short Hills, New Jersey--(Newsfile Corp. - September 7, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab ("LENZ®"), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor ("GM-CSF"), today announced presentation and participation in two healthcare focused investor conferences in September 2022. Details of the presentation and panel participation are as follows:H.C. Wainwright 24t |
Humanigen Reports Second Quarter 2022 Financial ResultsSHORT HILLS, N.J., August 12, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022. |
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical MilestonesShort Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today announced a strategic realignment of its pipeline and resources to achieve key clinical milestones. The Company plans to accelerate the development of lenzilumab in chronic myelomonocytic leukemia ("CMML"), a |